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Abstract
Objective The objective of this prospective multicenter
study was to obtain insight into the severity and burden of
hair loss among cancer patients treated with chemotherapy.
In addition, we described the effectiveness and burden of
scalp cooling and the satisfaction with wigs, with hair
regrowth, and with body image.
Materials and methods Breast cancer patients treated with
(n=98) and without (n=168) scalp cooling completed
questionnaires before chemotherapy and 3 weeks and 6
months after completion of chemotherapy.
Results Scalp cooling was effective in preventing chemo-
therapy-induced hair loss in 32 of 62 available patients
(52%). Even though patients knew hair loss was temporary,
it was a burden to 54% of them (n=100). Scalp cooling was
a burden for only 17 out of 51 patients (33%). Most
patients who used a wig or head cover were satisfied with it
(82%, n=126). Patients were moderately satisfied with the
regrowth of their hair after chemotherapy (mean 11.6; SD
2.53; range 0–20). Successfully cooled patients rated their
hair as less important for their body image compared to
patients who did experience hair loss (p=0.014).
Discussion Chemotherapy-induced hair loss is perceived as
burdensome. It may be prevented by offering scalp cooling
which is often an effective method to prevent this form of
hair loss and is tolerated well by patients. However, if
possible, scalp-cooling techniques should be improved and
their effectiveness should be increased because if scalp
cooling is unsuccessful, patients’ rate their hair loss as more
burdensome compared to noncooled patients.
Keywords Breast cancer . Scalp cooling . Hair loss .
Alopecia . Chemotherapy .Wig . Body image
Introduction
To date, the majority of breast cancer patients are treated with
surgery, often in combination with radiotherapy. These
therapies are often combined with chemotherapy (Dutch
guidelines; http://www.oncoline.nl), which may cause severe
side effects [19]. Patients rate hair loss as among the most
severe side effects of chemotherapy [4, 7, 9, 12, 22–24, 27,
37]. Since the 1970s, preventive efforts such as tourniquet,
medication, and scalp cooling have been applied to prevent
chemotherapy-induced hair loss [10]. Currently, scalp cool-
ing is the most commonly used method.
Seven randomized clinical studies have been published
which examined the effectiveness of scalp cooling [13, 16,
Support Care Cancer (2009) 17:181–189
DOI 10.1007/s00520-008-0475-4
Mols and Hurk contributed equally to this work.
F. Mols
CoRPS—Center of Research on Psychology in Somatic Diseases,
Tilburg University,
Tilburg, the Netherlands
F. Mols : C. van den Hurk :W. Breed
Comprehensive Cancer Center South (CCCS),
Eindhoven Cancer Registry,
Eindhoven, the Netherlands
C. van den Hurk
Department of Clinical Oncology,
Leiden University Medical Center,
Leiden, the Netherlands
A. Vingerhoets
Clinical Psychology Section, Tilburg University,
Tilburg, the Netherlands
F. Mols (*)
CoRPS, Department of Medical Psychology, Tilburg University,
Tilburg, the Netherlands
e-mail: F.Mols@uvt.nl
21, 25, 30, 34, 36]. These studies randomized a total of 233
patients. In six of these studies, scalp cooling was
considered to be effective. The average reported success
rate of scalp cooling in studies carried out before 1995, with a
total number of 1,563 patients, was 56% and from 1995
onwards the success rate was 73%with a total of 1,047 patients
included [17]. Despite this relatively high success rate, scalp
cooling offered is very limited; e.g., in February 2008, only
36% of all Dutch hospitals offered scalp cooling and,
moreover, only to a selected number of patients. Reasons
for this are, among others, the underestimation of the impact
of hair loss and overestimation of the burden of scalp cooling
on a patient by the oncologists and nurses and the lack of
knowledge on the current effectiveness of scalp cooling.
The present study is the first more systematic study that
specifically addresses quality of life and scalp-cooling
satisfaction in a multicenter context and has three main
objectives. The first objective was to obtain insight into the
severity and burden of hair loss among cancer patients
treated with chemotherapy. The second objective was to
describe the effectiveness and burden of scalp cooling. The
third objective was to describe the satisfaction with a wig
and with hair regrowth in patients who lost their hair after
chemotherapy (because they did not receive scalp cooling
or because scalp cooling failed). The final objective of this
study was to measure the difference in body image between
patients who were or were not treated with scalp cooling.
Materials and methods
Setting and participants
Breast cancer patients were enrolled in this prospective
multicenter study between October 2004 and February
2007. Thirteen hospital locations participated in this study,
with six offering scalp cooling. If patients in the scalp-
cooling hospitals did not chose for scalp cooling, they were
not included in this study.
Specialized oncology nurses informed patients about the
study. Patients who decided to participate received a set of
questionnaires before the start of chemotherapy, 3 weeks
after the last cycle of chemotherapy and 6 months after
chemotherapy. If a questionnaire was not returned, the
patient received a reminder. Approval for this study was
obtained from the Medical Ethics Committees of all
participating hospitals. All study participants provided
written informed consent.
Inclusion and exclusion criteria
Inclusion criteria were treatment for breast cancer with
one of the following intravenous chemotherapies: four
or six adriamycine (60 mg/m2) and cyclophosphamide
(600 mg/m2) treatments; five or six 5-fluorouracil
(500 mg/m2), epirubicine (90 mg/m2), and cyclophospha-
mide (500 mg/m2) treatments; five or six 5-fluorouracil
(500 mg/m2), adriamycine (50 mg/m2), and cyclophos-
phamide (500 mg/m2) treatments; and five or six docetaxel
(75 mg/m2), adriamycine (50 mg/m2), and cyclophospha-
mide (500 mg/m2) treatments. These chemotherapies had
to be given in the adjuvant setting in a 21-day cycle.
Patients treated with intravenous trastuzumab for a year
following chemotherapy were excluded because of the
possible influence of long-lasting intensive contact with
oncology nurses and other cancer patients on the measures.
Patients were excluded if they lacked basic proficiency in
Dutch, if they were unable to understand the patient
information folder, or if they suffered from alopecia before
the onset of chemotherapy.
Measures
Patient and tumor characteristics
The measured patient and tumor characteristics were date of
birth, marital status, educational level, type of surgery, and
lymph node dissection.
Severity of hair loss
The severity and importance of hair loss was measured by
asking patients if they felt the need to wear a wig or other
head covering. We defined the success of cooling on the
basis of whether the patient reported the use of a wig or
head covering. Furthermore, the severity of hair loss was
reported by patients on the four-point scale for alopecia of
the World Health Organization (WHO) with grade 0 for no
hair loss, grade 1 for mild hair loss, grade 2 for pronounced
hair loss, and grade 3 for total hair loss [40]. In addition, a
visual analog scale (VAS) was applied ranging from 0 for
no hair loss to 100 for total baldness. The severity of hair
loss was measured 3 weeks after the last cycle of
chemotherapy.
Burden of hair loss
A newly developed questionnaire assessed the impact of
hair loss. Part of the items were selected from question-
naires with respect to alopecia androgenetica [6, 11, 15];
other items were self-defined based on discussions with
female cancer patients. This measure consisted of 40
statements that could be rated on a four-point Likert scale
ranging from “not at all” to “very much.” Higher scores
indicated higher burden of hair loss. The answers on the
four-point Likert scale were divided into two groups,
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namely, patients who did or did not agree with a particular
statement. Patients who did not receive scalp cooling as well
as scalp-cooled patients who reported hair loss (defined as
WHO score grades 1, 2, or 3) completed the questionnaire 3
weeks and 6 months following chemotherapy.
Burden of scalp cooling
The burden of scalp cooling was evaluated by nine self-
defined items which were based on complaints reported by
patients who were treated with scalp cooling in the past.
The items concerned the psychological burden, physical
effects, and the influence of uncertainty about the final
result of cooling. Response format was a six-point Likert
scale ranging from “not at all” to “a lot.” Higher scores thus
indicate a higher burden of scalp cooling. The answers on
the six-point Likert scale were divided into two groups,
namely, patients who did or did not agree with a particular
statement. Furthermore, patients were asked whether or not
they had taken pain killers during scalp cooling.
This questionnaire was completed by 51 out of 98 scalp-
cooled patients. This was due to the fact that this
questionnaire was added to our set of questionnaires at a
later stage and only in some of the hospitals which offered
scalp cooling. Since patients were asked to fill out this
questionnaire after each cooling, we received a total of 153
completed questionnaires.
Wig use
Patients were asked what kind of head covering they used
and if they wore the head covering inside the house, only
outside the house, or both.
A newly developed questionnaire additionally evalu-
ated the satisfaction with wigs and head coverings and
was based on consultations with an expert panel (nurses
and patients). This measure consisted of 18 statements
rated on a four-point Likert scale ranging from “not at
all” to “very much.” Higher scores indicated higher
levels of satisfaction with wigs or head coverings.
Patients completed the questionnaire 3 weeks and 6
months following chemotherapy.
Hair regrowth
Satisfaction with hair regrowth was measured by a five-
item questionnaire addressing the rapidity of regrowth,
length and thickness, color, and hair style (curly or
straight). The answer categories were rated on a four-point
Likert scale ranging from “not at all” to “very much.”
Higher scores indicated higher levels of satisfaction with
hair regrowth. The answers on the four-point Likert scale
were divided into two groups, namely, patients who were or
were not satisfied with hair regrowth. The questionnaire
was filled out 6 months after completing chemotherapy by
patients who reported a score between 1 and 3 on the WHO
scale for hair loss.
Body image
Body image was assessed with the revised version of the
body image scale (BIS), consisting of ten items rated on a
four-point Likert scale ranging from “not at all” to “very
much.” The sum score of the ten items ranged from 0 to 30
with higher scores representing increased symptoms or
distress with regard to body image. The BIS has high
reliability (Cronbach’s alpha 0.93) and validity [18].
Concern over body image was assessed by the
Measure of Body Apperception (MBA) questionnaire
[5]. Scores were calculated for two subscales, namely,
“concern about physical appearance” and “concern about
body integrity.” These subscales both consisted of four
items and measured personal investment in both aspects of
body image, rather than assessing the body image the
person currently holds [5]. Two self-defined items were
added to the MBA to measure the importance of hair for a
person’s body image. Response options of the subscales
and self-defined items ranged from “strongly agree” to
“strongly disagree.” The scores were rated on a scale from
1 to 5, with higher scores meaning more concerns or
higher importance. This questionnaire was completed
before chemotherapy and 3 weeks after the completion
of chemotherapy.
Statistical analyses
Statistical analyses were performed using SAS (version 9.1
for Windows, SAS institute Inc., Cary, NC, USA). Patient
and tumor characteristics were compared between scalp-
cooled patients and not scalp-cooled patients by chi-square
tests for categorical variables.
From the questionnaire on the burden of hair loss, ten
statements were selected that caused the most burden to
patients. We reported the number and percentage of
questionnaires on which the statements were answered
affirmatively. The same procedure was followed for all
statements on the questionnaires: “burden of scalp cooling,”
“hair regrowth,” and “wig use.”
One week prior to chemotherapy, body image was
compared between those who were going to be treated
with scalp cooling and those who were not. Three weeks
after chemotherapy, body image was compared between
patients that were successfully cooled, not successfully
cooled, and patients that did not receive scalp cooling. All
group comparisons were made with analyses of variance
followed by Tukey’s test for multiple group comparison.
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Results
Patient and tumor characteristics
Ninety-eight patients received scalp cooling and 168 control
patients were included who were treated in hospitals where
no scalp cooling was available. The participants received the
questionnaires at three points in time. The numbers of
participants, according to measurement moment, are pre-
sented in Fig. 1. In total, 184 (68%) participants responded.
Dropout during the study occurred due to a variety of
reasons. Most often mentioned were logistical problems.
Patient and tumor characteristics of breast cancer
patients treated with or without scalp cooling are presented
in Table 1. These characteristics did not differ significantly
between both patient groups.
Severity of hair loss
Three weeks after chemotherapy, data were available of
65% of cooled patients (n=64) and 89% of not cooled
patients (n=149). Scalp cooling was effective in prevent-
ing chemotherapy-induced hair loss in 32 of 62 evaluable
patients. Data on two patients were missing; therefore,
they were excluded from further analyses (Fig. 1). In
patients who did not receive scalp cooling (n=149), all
but four needed a wig or head cover. These four patients
were however completely bald. Because of the low






Legend:  Dropout during the study occurred due to a variety of reasons. Most often 
mentioned were logistical problems. 
13 hospital locations participated in this study.
98 patients included
98 questionnaires available from measurement 1 
(before the start of chemotherapy) 
5 hospitals offered scalp cooling 8 hospitals did not offer scalp cooling
168 patients included 
168 questionnaires available from measurement 1 
(before the start of chemotherapy) 
64 questionnaires available from measurement 2  
 (3 weeks after chemotherapy) 
32 no head cover 
30 head cover 
2 unknown 
149 questionnaires available from measurement 2  
(3 weeks after chemotherapy) 
4 no head cover 
145 head cover 
55 questionnaires available from measurement 3 
(6 months after chemotherapy) 
26 no head cover 
27 head cover 
2 unknown 
129 questionnaires available from measurement 3  
(6 months after chemotherapy) 
2 no head cover 
127 head cover 
 
Fig. 1 Flow chart of the data
collection process
Table 1 Sociodemographic and clinical characteristics of breast









Mean age at time of survey 49.8 49.7
Surgery
Total mastectomy 43 (44) 94 (56) 0.1609
Breast conserving surgery 50 (51) 68 (40)
Lymph node dissection
Yes 79 (81) 129 (77) 0.4238
No 15 (15) 35 (21)
Marital status
Married 76 (78) 124 (74) 0.3060
Not married or divorced 11 (11) 29 (17)
Living together 11 (11) 13 (8)
Education level
Low 42 (43) 91 (55) 0.1619
Medium 31 (32) 42 (26)
High 24 (25) 31 (19)
Missing 1 (1) 4 (2)
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The mean rating of hair loss on the VAS scale among
successfully cooled patients was 49 (range 17 to 97) while
not successfully cooled patients rated a mean of 79 (range
30 to 100). Patients who did not receive scalp cooling
reported most hair loss, namely, a mean of 85 (range 9 to
100). These differences in self-reported hair loss were
statistically significant (p<0.001).
Extent of hair loss was also rated by patients on the
WHO scale. The mean WHO score among successfully
cooled patients 3 weeks after chemotherapy was 1.4 (range
0 to 3) while not successfully cooled patients rated a mean
of 2.6 (range 0 to 3). Patients who did not receive scalp
cooling reported the most hair loss, namely, a mean of 2.9
(range 0 to 3).
Burden of hair loss
Out of a list of 40 statements about the burden of hair loss to a
patient, the ten statements that were most frequently confirmed
3 weeks and 6 months following chemotherapy were reported
in Table 2. On 71% of questionnaires, it was stated that hair
loss made patients feel unattractive and 58% of questionnaires
stated that hair loss was a problem for patients. Furthermore,
54% of questionnaires showed that, even though patients
knew hair loss was temporary, it was a burden to them.
Burden of scalp cooling
Only 51 of 98 scalp-cooled patients completed the question-
naire about the burden of scalp cooling. These were the
patients who underwent a maximum of six cycles of scalp
cooling and were thus asked to complete a maximum of six
questionnaires. Fifty-one patients filled out the questionnaire
during the first cycle; 46 patients also filled out the second
questionnaire; 31 patients also did questionnaire three; 16
patients did questionnaire four; nine patients finished the fifth
questionnaire and no one finished the last one. Therefore, data
of 153 questionnaires were obtained.
In Table 3, we listed the statements of the questionnaire
on the burden of scalp cooling and the percentage of
questionnaires on which the statements were answered
confirmatively. Furthermore, we added data on the number
and percentage of patients who answered the statements
confirmatively on one or more occasions. On 25 question-
naires (16%), it was indicated that scalp cooling was a
burden; this was filled out by 17 patients on one or more
occasions. The statement; “I was able to tolerate the cooling
of my scalp” was answered affirmatively on 53 question-
naires (35%) by 27 patients. Twenty-one questionnaires
(14%) indicated that scalp cooling gave patients (n=12) a
headache. However, only nine patients occasionally took a
pain killer to relieve a headache (data not shown). On 74
questionnaires (48%), it was indicated that patients thought
frequently about the result of scalp cooling; this was filled
out by 31 patients on one or more occasions.
Wig use
All patients with severe hair loss induced by chemotherapy
(n=175; 30 not successfully cooled and 145 not cooled)
Table 2 Ten statements that caused the most burden of hair loss 3
weeks and 6 months after chemotherapy
Statementsa n (%)b
I do not feel attractive because of my hair loss 130 (71)
Hair loss was a problem for me 106 (58)
Even though my hair loss was temporary, I found it a
burden
100 (54)
I was not satisfied with myself because of my hair loss 92 (50)
I was very aware of myself because of my hair loss 87 (47)
In the past few weeks–months, I checked my hair loss in the
mirror regularly
86 (47)
I talked to my friends about my hair loss 82 (45)
The hair loss of my eyes (eyelashes) was a burden to me 67 (36)
The hair loss of my eyebrows was a burden to me 69 (38)
I was looking for some elucidation about my looks because
of my hair loss
61 (33)
n Number of questionnaires filled out by patients who did not receive
scalp cooling as well as scalp-cooled patients who reported hair loss, 3
weeks and 6 months following chemotherapy
a Out of a list of 40 statements, ten statements about hair loss that
caused the most burden to patients are reported in this table.
b The number and percentage of patients that answered the statements
confirmatively on one or more occasions.






Scalp cooling was a burden to me 25 (16) 17 (33)
The cooling was cold 43 (28) 20 (39)
The cooling gave me a headache 21 (14) 12 (24)
The ‘cold cap’ was heavy 21 (14) 15 (29)
I was able to tolerate the cooling of
my scalp
53 (35) 27 (53)
I got dizzy during the cooling 14 (9) 10 (20)
I felt bored during the cooling 20 (13) 14 (27)
I worry a lot lately about the
possibility of failure of scalp
cooling
48 (31) 22 (43)
Lately, I thought a lot about the
result of scalp cooling
74 (48) 31 (61)
a Statements are listed in this table in the same order of appearance as
in the questionnaire.
b The number and percentage of questionnaires on which the state-
ments were answered affirmatively.
c The number and percentage of patients that answered the statements
confirmatively on one or more occasions.
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reported the use of a wig and/or other head cover. Most
patients used more than one head cover; a wig was used by
81% of patients, 51% used a scarf, 23% used a cap, and 8%
wore a hat. Seventy-six percent of patients who used a wig
or head cover made use of it both inside and outside the
house. Furthermore, 37% reported to wear a wig or head
cover merely outdoors and only one patient wore it just
indoors.
In Table 4, we listed all 18 statements of the question-
naire on wig use and the percentage of questionnaires that
were answered affirmatively 3 weeks and 6 months after
chemotherapy. On 126 questionnaires (82%), it was stated
that patients were satisfied with their wig; it looked a lot like
their own hair (n=103; 67%); it fitted nicely round their
scalp (n=119; 77%) and on only a minority of question-
naires (n=10; 1%) patients complained about irritation to
the skin. However, in 91 questionnaires (59%), patients
stated that they felt that their wig was expensive and that
they were constantly aware of wearing it (n=96; 62%).
Hair regrowth
Six months after chemotherapy, patients who had suffered
from hair loss (n=172) were moderately satisfied with hair
regrowth (mean 11.6; SD 2.53; range 0–20). Satisfaction
with hair regrowth did not differ significantly between
patients who underwent scalp cooling and the control group.
Most patients indicated that they were satisfied with the
thickness of their hair (86%, n=147) and with the speed at
which their hair grows (75%, n=129). In addition, most
patients were satisfied with the texture of their hair (curly or
straight; 73%, n=125), the current length of their hair
(72%, n=121), and the color of their hair (57%, n=98).
Body image
Before the initiation of chemotherapy, participants in the
hospitals that offered scalp cooling reported somewhat more
concern about appearance (mean 3.27 vs. 3.02; p=0.03)
compared to patients in the hospitals that did not offer scalp
cooling (Table 5). Three weeks after chemotherapy, scalp-
cooled patients who did not need a wig reported that their
hair had a significant (p=0.01) lower importance for their
body image (mean 4.09; SD 0.86) compared to unsuccess-
fully scalp-cooled patients who needed a wig (mean 4.50;
SD 0.63) and patients not treated with scalp cooling (mean
4.27; SD 0.81).
Discussion
The aim of the present study was to obtain insight into the
impact that scalp cooling to prevent hair loss during
chemotherapy has on the patient. Furthermore, the objective
was to evaluate the burden of hair loss and the satisfaction
with wigs and with hair regrowth in patients who did lose
their hair. Finally, we compared body image between
patients who did and did not experience hair loss.
The effectiveness of scalp cooling
Approximately 50% of patients that received scalp cooling
did not need a wig and were therefore considered
successfully cooled. This percentage seems somewhat low
because the average success rate of scalp cooling in studies
published after 1995 was 73% [17]. In the literature, wide
variations of success rates of scalp cooling have been
reported. The success depends upon many factors like type
of applied cytostatics, doses, number of chemotherapy
courses, admission methods, and scalp-cooling method [1,
Table 4 The burden of wearing a wig or head cover 3 weeks and 6
months after chemotherapy
Statementsa n (%)b
My wig fitted nicely round my scalp 119 (77)
I was constantly aware of wearing a wig or head cover 96 (62)
Wearing a head cover made me feel watched by other
people
35 (23)
My wig caused irritation to the skin 10 (1)
I was satisfied with my wig or head cover 126 (82)
My wig looked a lot like my own hair 103 (67)
When wearing a wig, I felt just as attractive as before my
hair fell out
73 (47)
By wearing a wig, I felt confident about myself 81 (53)
It bothered me that, on some occasions, wearing a wig
caused sweating
56 (36)
I felt ashamed of myself when I was not wearing my wig or
head cover
53 (34)
My partner preferred to see me with my wig or head cover
instead of without
29 (19)
Wearing a wig made my head feel warm and that
bothered me
51 (33)
With activities like exercising, my wig was an obstruction 54 (35)
I was worried about the possibility of my wig moving or
falling off
39 (25)
My kids preferred to see me with my wig or head cover
instead of without
50 (32)
My wig was expensive 91 (59)
When wearing a wig, I felt more feminine compared to not
wearing a wig
85 (55)
My wig was easily distinguishable from my own hair 12 (1)
a Statements are listed in this table in the same order of appearance as
in the questionnaire. In this table, data were included from 3 weeks
and 6 months after chemotherapy for patients wearing a wig or head
cover.
b The number and percentage of questionnaires on which the state-
ments were answered affirmatively.
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8, 36]. The recent, more intensive, adjuvant chemotherapy
treatments in breast cancer may explain the relatively low
success percentage of about 50% in this study. Furthermore,
the definition of successfully cooled differs considerably
among studies. Wearing a wig or head cover may be
considered the most important criterion to determine if
patients consider their scalp cooling as successful. However,
graded scales, like the WHO scale, are also used [17]. In this
study, we used both methods. In addition, our relatively low
success rate of scalp cooling was defined 3 weeks after the
completion of chemotherapy. However, it is possible that
success of scalp cooling in other studies is measured earlier
(e.g., cycle 3) and not always at the end of all cycles. This
could also cause a difference in success rates between other
studies and our study. Another possible explanation for our
rather low success rate is the fact that the present study is a
multicenter study which generally is associated with lower
success rates in all kinds of evaluation studies compared to
studies performed in a single center. Also, publication bias
might be a factor; it is possible that studies having achieved
low success rates have not been published after 1995.
The burden of hair loss
Hair loss was rated as being a source of distress to patients
and this finding confirms results reported in the literature
on this topic. A number of studies have shown that a
considerable number of cancer patients experience alopecia
as distressing [23, 31, 39]. Furthermore, alopecia is ranked
among the three most troublesome side effects of chemo-
therapy, together with vomiting and nausea [4, 7, 37].
The burden of scalp cooling
This study showed that patients did not perceive scalp
cooling as being burdensome. We found low rates of
complaints which is in accordance with literature about the
acceptability and tolerance of scalp cooling [17, 20, 26, 32–
34]. Twelve patients indicated that scalp cooling gave them
a headache; however, only nine patients occasionally took a
pain killer to relieve a headache.
The satisfaction with wigs
All respondents coped with hair loss with a strategy
involving camouflaging and hiding; they wore wigs or
other head covers in an attempt to hide their hair loss.
Alopecia is in particular hided outside the house, when
being exposed to others with whom the patient does not
wish to share the visible stigma. On the other hand,
corroborating previous research [35], an important minority
of patients do not hide alopecia inside their own homes
when being with their partner, family, and friends who
know about the hair loss. Wearing a wig “repairs” your
physical appearance, restores corporal integrity, and pre-
vents the patients and others of being constantly reminded
of cancer. Patients in our study reported that their wigs were
not easily distinguishable from their own hair which
supports the idea that wigs were mostly worn to look
normal, in any case not looking sick, for themselves and
others [39].
The satisfaction with hair regrowth
Hair loss from chemotherapy is temporary; however, how it
will grow back is unpredictable; sometimes, the new hair
has a different color or texture [2, 14, 39]. Six months after
having completed chemotherapy, patients were generally
satisfied with their hair regrowth. Since nobody had
experienced previous chemotherapy, they did not know
what they could expect concerning the regrowth of hair.
Patients who experienced severe hair loss or complete
baldness have several centimeters of hair within half a year.
In patients with bald spots or thinned hair (because scalp
cooling was not totally preventive for hair loss and who did
not shave their hair), some hair regrowth directly causes a
Table 5 Body image 1 week prior to chemotherapy and 3 weeks after chemotherapy among patients treated with and without scalp cooling












Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Body image (BIS; range 0–30)
Total score 7.71 (4.97) 7.24 (5.76) 0.5130 9.13 (6.00) 12.18 (5.94) 9.74 (5.93) 0.0984
Concern about body image (MBA; range 1–5)
Concern about appearance 3.27 (0.76) 3.02 (0.89) 0.0274 2.97 (0.88) 3.23 (0.91) 3.08 (0.87) 0.2005
Concern about body integrity 2.59 (0.89) 2.49 (1.02) 0.4393 2.59 (1.00) 3.02 (0.99) 2.66 (0.96) 0.9060
Importance of hair for body image
My hair is important to me 4.43 (0.83) 4.25 (0.83) 0.0551 4.09 (0.86) 4.50 (0.63) 4.27 (0.81) 0.0141
My hair is important for my appearance 4.25 (0.68) 4.09 (0.93) 0.1494 3.94 (0.84) 4.40 (0.62) 4.14 (0.86) 0.0719
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thicker head of hair and camouflaging is not needed
anymore. Patients in this study were very satisfied with
the texture of their hair but were less satisfied with its color.
Body image
Body image did not differ between patients who did and
did not lose their hair 3 weeks after chemotherapy. These
findings confirm the results of a prior study among 77
cancer patients receiving chemotherapy, which also dem-
onstrated that patients with alopecia had comparable scores
on body image compared to those without alopecia. The
negative effect of hair loss on body image may have been
minimized by the process of adaptation to hair loss [38] and
possibly by the positive effects of the wig. However, a
study on changes in body image during chemotherapy
among 136 women with gynecologic malignancies who
experienced alopecia showed that chemotherapy-induced
alopecia had an adverse effect on body image [29]. In
addition, a study among 40 cancer patients receiving
chemotherapy showed a significant difference in body
image between patients with alopecia and patients without
alopecia [3]. Furthermore, a study among 29 German
women with a gynecological malignancy who lost their
hair during chemotherapy found that regrowth of hair after
chemotherapy did not necessarily imply recovery of the
declined body image [28]. The studies mentioned above all
used different methods to measure body image; moreover,
these studies did not include patients treated with scalp
cooling. Comparisons with the current study are therefore
problematic.
In addition, our results showed that, 3 weeks after
chemotherapy, successfully cooled patients rated their hair
as less important for their body image compared to patients
who did experience hair loss. These results may indicate
that people only became aware of the importance of hair for
their body image once they lost it.
Limitations
This is an observational study and patient self-selection was
therefore inevitable. We do not know how many patients
were eligible for scalp cooling and to how many of them it
was offered and, finally, how many have accepted that
offer. Dropout during the study was most often caused by
logistical problems. Furthermore, the sample of scalp-cooled
patients was relatively small, which made subanalyses less
powerful. In addition, some of the questionnaires used in this
study are relatively new and their psychometric characteristics
are currently unknown. Nevertheless, the results of this study
form an important contribution to the limited information
available on scalp cooling to prevent chemotherapy-induced
hair loss in cancer patients.
Final remarks
In conclusion, the present study is the first more systematic
study that specifically addresses scalp-cooling satisfaction in a
multicenter context. This study showed that chemotherapy-
induced hair loss is stressful to the majority of breast cancer
patients. Hair loss may be prevented by scalp cooling although
the success rate in this study was limited. Nevertheless, scalp
cooling can be an effective method to prevent hair loss and is
tolerated well by patients. However, scalp cooling techniques
should be improved because if scalp cooling is unsuccessful,
patients’ rate their hair loss as more burdensome compared to
patients who did not receive scalp cooling.
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